Cost-analysis of inpatient and outpatient parenteral antimicrobial therapy in orthopaedics: A systematic literature review

Standard

Cost-analysis of inpatient and outpatient parenteral antimicrobial therapy in orthopaedics: A systematic literature review. / Boese, Christoph Kolja; Lechler, Philipp; Frink, Michael; Hackl, Michael; Eysel, Peer; Ries, Christian.

In: WORLD J CLIN CASES, Vol. 7, No. 14, 26.07.2019, p. 1825-1836.

Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

Harvard

APA

Vancouver

Bibtex

@article{981084ade0b5445d80ae142f2a9ab962,
title = "Cost-analysis of inpatient and outpatient parenteral antimicrobial therapy in orthopaedics: A systematic literature review",
abstract = "BACKGROUND: Increasing numbers of total joint arthroplasties and consecutive revision surgery are associated with the risk of periprosthetic joint infections (PPJI). Treatment of PPJI is complex and associated with immense socio-economic burden. One treatment aspect is parenteral antiinfective therapy, which usually requires an inpatient setting [Inpatient parenteral antibiotic therapy (IPAT)]. An alternative is outpatient parenteral treatment [Outpatient parenteral antibiotic therapy (OPAT)]. To conduct a health economic cost-benefit analysis of OPAT, a detailed cost analysis of IPAT and OPAT is required. So far, there is a lack of knowledge on the health economic effects of IPAT and OPAT for PPJI.AIM: To review an economic comparison of IPAT and OPAT.METHODS: A systematic literature review was performed through Medline following the PRISMA guidelines.RESULTS: Of 619 identified studies, 174 included information of interest and 21 studies were included for quantitative analysis of OPAT and IPAT costs. Except for one study, all showed relevant cost savings for OPAT compared to IPAT. Costs for IPAT were between 1.10 to 17.34 times higher than those for OPAT.CONCLUSION: There are only few reports on OPAT for PPJI. Detailed analyses to support economic or clinical guidelines are therefore limited. There is good clinical evidence supporting economic benefits of OPAT, but more high quality studies are needed for PPJI.",
author = "Boese, {Christoph Kolja} and Philipp Lechler and Michael Frink and Michael Hackl and Peer Eysel and Christian Ries",
year = "2019",
month = jul,
day = "26",
doi = "10.12998/wjcc.v7.i14.1825",
language = "English",
volume = "7",
pages = "1825--1836",
journal = "WORLD J CLIN CASES",
issn = "2307-8960",
publisher = "Baishideng Publishing Group",
number = "14",

}

RIS

TY - JOUR

T1 - Cost-analysis of inpatient and outpatient parenteral antimicrobial therapy in orthopaedics: A systematic literature review

AU - Boese, Christoph Kolja

AU - Lechler, Philipp

AU - Frink, Michael

AU - Hackl, Michael

AU - Eysel, Peer

AU - Ries, Christian

PY - 2019/7/26

Y1 - 2019/7/26

N2 - BACKGROUND: Increasing numbers of total joint arthroplasties and consecutive revision surgery are associated with the risk of periprosthetic joint infections (PPJI). Treatment of PPJI is complex and associated with immense socio-economic burden. One treatment aspect is parenteral antiinfective therapy, which usually requires an inpatient setting [Inpatient parenteral antibiotic therapy (IPAT)]. An alternative is outpatient parenteral treatment [Outpatient parenteral antibiotic therapy (OPAT)]. To conduct a health economic cost-benefit analysis of OPAT, a detailed cost analysis of IPAT and OPAT is required. So far, there is a lack of knowledge on the health economic effects of IPAT and OPAT for PPJI.AIM: To review an economic comparison of IPAT and OPAT.METHODS: A systematic literature review was performed through Medline following the PRISMA guidelines.RESULTS: Of 619 identified studies, 174 included information of interest and 21 studies were included for quantitative analysis of OPAT and IPAT costs. Except for one study, all showed relevant cost savings for OPAT compared to IPAT. Costs for IPAT were between 1.10 to 17.34 times higher than those for OPAT.CONCLUSION: There are only few reports on OPAT for PPJI. Detailed analyses to support economic or clinical guidelines are therefore limited. There is good clinical evidence supporting economic benefits of OPAT, but more high quality studies are needed for PPJI.

AB - BACKGROUND: Increasing numbers of total joint arthroplasties and consecutive revision surgery are associated with the risk of periprosthetic joint infections (PPJI). Treatment of PPJI is complex and associated with immense socio-economic burden. One treatment aspect is parenteral antiinfective therapy, which usually requires an inpatient setting [Inpatient parenteral antibiotic therapy (IPAT)]. An alternative is outpatient parenteral treatment [Outpatient parenteral antibiotic therapy (OPAT)]. To conduct a health economic cost-benefit analysis of OPAT, a detailed cost analysis of IPAT and OPAT is required. So far, there is a lack of knowledge on the health economic effects of IPAT and OPAT for PPJI.AIM: To review an economic comparison of IPAT and OPAT.METHODS: A systematic literature review was performed through Medline following the PRISMA guidelines.RESULTS: Of 619 identified studies, 174 included information of interest and 21 studies were included for quantitative analysis of OPAT and IPAT costs. Except for one study, all showed relevant cost savings for OPAT compared to IPAT. Costs for IPAT were between 1.10 to 17.34 times higher than those for OPAT.CONCLUSION: There are only few reports on OPAT for PPJI. Detailed analyses to support economic or clinical guidelines are therefore limited. There is good clinical evidence supporting economic benefits of OPAT, but more high quality studies are needed for PPJI.

U2 - 10.12998/wjcc.v7.i14.1825

DO - 10.12998/wjcc.v7.i14.1825

M3 - SCORING: Journal article

C2 - 31417928

VL - 7

SP - 1825

EP - 1836

JO - WORLD J CLIN CASES

JF - WORLD J CLIN CASES

SN - 2307-8960

IS - 14

ER -